GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025
2025年1月29日 - 6:30AM
ビジネスワイヤ（英語）
GeneDx (Nasdaq: WGS), a leader in delivering improved health
outcomes through genomic insights, announced it will release
financial results for the fourth quarter 2024 and the full year
2024 before the market opens on Tuesday, February 18, 2025.
Management will host a conference call that day to discuss fourth
quarter 2024 and full year 2024 financial and operating results at
8:30 a.m. Eastern Time.
Conference Call Details
Investors interested in listening to the conference call are
required to register online. A live and archived webcast of the
event will be available on the “Events” section of the GeneDx
investor relations website at https://ir.genedx.com/.
About GeneDx
At GeneDx (Nasdaq: WGS), we believe that everyone deserves
personalized, targeted medical care—and that it all begins with a
genetic diagnosis. Fueled by one of the world’s largest rare
disease data sets, our industry-leading exome and genome tests
translate complex genomic data into clinical answers that unlock
personalized health plans, accelerate drug discovery, and improve
health system efficiencies. For more information, please visit
genedx.com and connect with us on LinkedIn, Facebook, and
Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250128102430/en/
Investor Relations Contact: Investors@GeneDx.com
Media Contact: Press@GeneDx.com
GeneDx (NASDAQ:WGS)
過去 株価チャート
から 12 2024 まで 1 2025
GeneDx (NASDAQ:WGS)
過去 株価チャート
から 1 2024 まで 1 2025
